A New Biologic for a Disease Still Being Defined
A single patient recently diagnosed with a disease still being defined by the same research that's now offering it a new treatment. The disagreement is between the more established option and the one that might spare him decades of a cycle the established option all but guarantees.
T.J., a 31-year-old software developer with a lifelong history of eczema and seasonal allergies, spent nearly two years bouncing between explanations for his abdominal pain, early satiety, and intermittent vomiting before biopsies from an EGD finally confirmed eosinophilic gastritis and duodenitis — dense eosinophilic infiltration well above diagnostic threshold in both the stomach and duodenum, with celiac disease, parasitic infection, and other secondary causes of eosinophilia formally excluded. His personal history of atopy — eczema since childhood, seasonal allergic rhinitis, a remote peanut allergy — fits the broader pattern increasingly recognized across the eosinophilic gastrointestinal disease spectrum, of which eosinophilic esophagitis is the best-characterized member and EG/EoD a real but still less-studied relative.
Corticosteroids, whether topical (swallowed budesonide, formulated to reach beyond the esophagus into the stomach and duodenum) or systemic, have been the default first-line treatment for EG/EoD largely by extrapolation from eosinophilic esophagitis's own better-established steroid response, and genuinely work for a meaningful share of patients — but relapse after steroid taper is common, and systemic exposure carries real cumulative toxicity in a 31-year-old facing a likely chronic, relapsing disease course.
Dupilumab, an IL-4 receptor alpha antagonist blocking both IL-4 and IL-13 signaling, received FDA approval for eosinophilic esophagitis in 2022 on the strength of real randomized trial data. What is genuinely new is DEGAS, a placebo-controlled Phase 2 proof-of-concept trial of 41 patients with eosinophilic gastritis reported by Rothenberg and colleagues in 2026, which cut mean gastric eosinophil counts by 50% at twelve weeks against 4% on placebo, with matching improvement in endoscopic and histologic scores. What DEGAS establishes is tissue-level benefit; it was not powered to settle whether symptoms follow, and it enrolled on gastric disease rather than on T.J.'s combined gastric-and-duodenal picture, which a larger trial is still recruiting to answer. It remains, as of T.J.'s diagnosis, without a formal FDA indication for EG/EoD specifically, making its use here an off-label decision resting on a real but still-developing trial base rather than an established standard. His remote peanut allergy, notably, has never involved his gastrointestinal tract directly — a detail the team confirmed explicitly, since food-allergen avoidance is a genuinely different intervention from anything being discussed today, and one his allergist had already ruled out as a contributing driver before this referral.
Sequencing therapy for a disease still being characterized
Corticosteroids remain the more established first-line option here — swallowed budesonide has a real track record across the eosinophilic GI disease spectrum, even though most of that evidence is extrapolated from eosinophilic esophagitis rather than EG/EoD specifically.
I'd start there, reserving dupilumab as the next step if he doesn't respond or relapses quickly after taper. That's still the sequencing most current guidance reflects, and it doesn't require an off-label prior authorization fight before we've tried the more established option.
I understand the sequencing argument, and I'm not dismissing budesonide's real track record.
What weighs on me is that he's 31, and this is very likely a chronic, relapsing disease — a treat-relapse-retreat steroid cycle over decades carries real cumulative toxicity, even with topical rather than systemic dosing. DEGAS gives us real placebo-controlled Phase 2 data in eosinophilic gastritis itself, not extrapolated from EoE — a 50% reduction in gastric eosinophils against 4% on placebo, with the endoscopic and histologic scores moving too. I'd be overselling it if I called that a symptom result; it isn't one yet. I'd rather start there for a patient this young facing a likely lifelong disease course.
The Phase 2 data are real, and I won't pretend they're not meaningful just because the FDA indication isn't there yet — that's a fair point about his age and the likely disease course I hadn't weighted heavily enough.
I'd support a short, defined trial of budesonide first — eight weeks, with a low threshold to move to dupilumab if he doesn't achieve real symptomatic and histologic response — rather than either committing him to years of steroid cycling or skipping straight to an off-label biologic before we've seen how he responds to the more established option.
An eight-week defined trial of swallowed budesonide started, with dupilumab named explicitly in his chart as the next step if symptomatic and histologic response is inadequate, rather than an open-ended steroid course or an immediate off-label biologic decision.
Genuinely reconciled through discussion — the Allergist/Immunologist's concern about his age and long-term steroid exposure shaped the trial's short, defined window and the explicit next-step plan, even though the sequencing itself stayed steroid-first.